Methylphenidate and brain activity in a reward/conflict paradigm: Role of the insula in task performance

European Neuropsychopharmacology

Volumn 24, Issue 6, 2014, Pages 897-906

  Ivanov, Iliyan ^a   Liu, Xun ^a,b   Clerkin, Suzanne ^a   Schulz, Kurt ^a   Fan, Jin ^a,c   Friston, Karl ^d   London, Edythe D ^e,f   Schwartz, Jeffrey ^e   Newcorn, Jeffrey H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF PSYCHOLOGY   (China)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention; FMRI; Insula; Reward; Stimulants

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT; OXYGEN;

ACCURACY; ADULT; ANTICIPATION; ARTICLE; ATTENTION; BOLD SIGNAL; CONFLICT; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; INSULA; MALE; MOTIVATION; NERVE CONDUCTION; NORMAL HUMAN; PRIORITY JOURNAL; REWARD; TASK PERFORMANCE; ASSOCIATION; BLOOD; BRAIN; BRAIN CORTEX; BRAIN MAPPING; DRUG EFFECTS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; VASCULARIZATION; YOUNG ADULT;

ADULT; ATTENTION; BRAIN; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; CONFLICT (PSYCHOLOGY); CUES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPHENIDATE; MIDDLE AGED; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; OXYGEN; REWARD; TASK PERFORMANCE AND ANALYSIS; YOUNG ADULT;

EID: 84899936839     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.01.017     Document Type: Article

References (43)

1. Arnsten A. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006, 31:2376-2383.
2. Berridge C., Devilbiss D., Andrzejewski M., Arnsten A., Kelley A., Schmeichel B., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 2006, 60:1111-1120.
3. Clerkin S., Schulz K., Halperin J., Newcorn J., Ivanov I., Tang C., et al. Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biol. Psychiatry 2009, 66(4):307-312.
4. Conners, K., 2000. Conners' Rating Scales-Revised Technical Manual. Multi Health Systems. North Tonawanda, New York.
5. Costa A., Riedel M., Pogarell O., Menzel-Zelnitschek F., Schwarz M., Reiser M., Möller H.J., Rubia K., Ettinger U. Methylphenidate effects on neural activity during response inhibition in healthy humans. Cereb. Cortex 2013, 23(5):1179-1189.
6. Craig A. How do you feel-now? The anterior insula and human awareness. Nat. Rev. Neurosci. 2009, 10(1):59-70.
7. Craig A. Significance of the insula for the evolution of human awareness of feelings from the body. Ann. N. Y. Acad. Sci. 2011, 1225:72-82.
8. Cyr J., Doxey N., Vigna C., Vigna M. Factorial composition of the SCL-90-R. J. Soc. Behav. Personal. 1988, 3(3):245-252.
9. Dodds C., Mueller U., Clark L., van Loon A., Cools R., Robbins T. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J. Neurosci. 2008, 28:5976-5982.
10. Fan J., McCandliss B.D., Fossella J., Flombaum J.I., Posner M.I. The activation of attentional networks. NeuroImage 2005, 26:471-479.
11. Farb N.A.S., Segal Z.V., Mayberg H., Bean J., McKeon D., Fatima Z., Anderson A.K. Attending to the present: mindfulness meditation reveals distinctneural modes of self-reference. Soc. Cogn. Affect. Neurosci. 2007, 2:313-322.
12. Foote S., Freedman R., AP O. Effects of putative neurotransmitters on neuronal activity in monkey auditory cortex. Brain Res. 1975, 86(2):229-242.
13. Friston K.J., Fletcher P., Josephs O., Holmes A., Rugg M.D., Turner R. Event-related fMRI: characterizing differential responses. NeuroImage 1998, 7:30-40.
14. Grabenhorst F., Rolls E. Value, pleasure and choice in the ventral prefrontal cortex. Trends Cogn. Sci. 2011, 15(2):56-67.
15. Hasenkam, P.W., Barsalou L.W. Effects of meditation experience on functional connectivity of distributed brain networks. Front. Hum. Neurosci. 2012, 6(38):1-14.
16. Ivanov I., Liu X., Shulz K., Fan J., London E., Friston K., et al. Parental substance abuse and function of the motivation and behavioral inhibition systems in drug-naïve youth. Psychiatry Res. 2012, 201(2):128-135.
17. Ivanov I., Liu X., Clerkin S., Friston K., Newcorn J., Fan J. Effects of motivation on reward and attentional networks: an fMRI study. Brain Behav. 2012, 2(6):741-753.
18. Klein T., Endrass T., Kathmann N., Neumann J., Cramon D., Ullsperger M. Neural correlates of error awareness. Neuroimage 2007, 2007(34):1774-1781.
19. Knutson B., Bjork J., Fong G., Hommer D., Mattay V., Weinberger D. Amphetamine modulates human incentive processing. Neuron 2004, 43:261-269.
20. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 1997, 68:2032-2037.
21. Linke J., Kirsch P., King A., Gass A., Hennerici M., Bonger A., et al. Motivational orientation modulates the neural response to reward. Neuroimage 2010, 49:2618-2625.
22. London E., Ernst M., S Grant S., Bonson K., Weinstein A. Orbitofrontal cortex and human drug abuse: functional imaging. Cerebral Cortex 2000, 10:334-342.
23. Marquand A., De Simoni S., O'Daly O., Williams S., Mourão-Miranda J., Mehta M. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology 2011, 36:1237-1247.
24. Marquand A., O'Daly O., De Simoni S., Alsop D., Maguire R., Williams S., et al. Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: a multi-class pattern recognition approach. NeuroImage 2012, 60(2012):1015-1024.
25. Mehta M., Owen A., Sahakian B., Mavaddat N., Pickard J., Robbins T. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 2000, 20:6.
26. Müller U., Suckling J., Zelaya F., Honey G., Faessel H., Williams S., et al. Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology 2005, 180(4):624-633.
27. Nichols T.E. Multiple testing corrections, nonparametric methods, and random field theory. Neuroimage 2012, 62(2):811-815.
28. Opris I., Santos L., Gerhardt G.A., Song D., Berger T.W., Hampson R.E., Deadwyler S.A. Prefrontal cortical microcircuits bind perception to executive control. Sci Rep. 2013, 2013(3):2285.
29. Pauls A., O'Daly O., Rubia K., Riedel W., Williams S., Mehta M. Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition. Biol. Psychiatry 2012, 72(2):142-149.
30. Paulus M., Rogalsky C., Simmons A., Feinstein J., Stein M. Increased activation in the right insula during risk-taking decision making is related to harm avoidance and neuroticism. Neuroimage 2003, 49:2618-2625.
31. Price D., Finniss D., Benedetti F. A Comprehensive review of the placebo effect: recent advances and current thought. Annu. Rev. Psychol. 2008, 59:565-590.
32. Robbins T., Arnsten A. The neuropsychopharmacology of fronto-executive function:monoaminergic modulation. Annu. Rev. Neurosci. 2009, 32:267-287.
33. Rolls E. Functions of the orbitofrontal and pregenual cingulate cortex in taste, olfaction, appetite and emotion. Acta. Physiol. Hung. 2008, 95(2):131-164.
34. Ryan J.J., Carruthers C.A., Miller L.J., Souheaver G.T., Gontkovsky S.T., Zehr M.D. Exploratory factor analysis of the Wechsler Abbreviated Scale of Intelligence (WASI) in adult standardization and clinical samples. Appl. Neuropsychol. 2003, 10:252-256.
35. Schulz K., Bédard A., Czarnecki R., Fan J. Preparatory activity and connectivity in dorsal anterior cingulate cortex for cognitive control. NeuroImage 2011, 57(1):242-250.
36. Schulz K., Fan J., Bedard A., Clerkin S., Ivanov I., Tang C., et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2012, 69(9):952-961.
37. Schwartz J.M., Begley S. The Mind and The Brain: Neuroplasticity and the Power of Mental Force 2002, Harper Collins, New York, NY.
38. Seeley W.W., Menon V., Schatzberg A.F., Keller J., Glover G.H., Kenna H., Reiss A.L., Greicius M.D. Dissociable intrinsic connectivity networks for salience processing and executive control. J. Neurosci. 2007, 27:2349-2356.
39. Seeman P., Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol. Psychiatry 1998, 3:386-396.
40. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch. Gen. Psychiatry 1992, 49:624-629.
41. Tomasi D., Volkow N., Wang G., Wang R., Telang F., Caparelli E., et al. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. NeuroImage 2011, 54(4):3101-3110.
42. Vaidya C., Austin G., Kirkorian G., Ridlehuber H., Desmond J., GH G., Gabrieli J. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. 1998, 95(24):14494-14499.
43. Westermeyer J., Yargic I., Thuras P. Michigan assessment-screening test for alcohol and drugs (MAST/AD): evaluation in a clinical sample. Am. J. Addict. 2004, 13:151-162.